Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Oracle Health Sciences Global Business Unit Strategy

Steve Rosenberg Senior Vice President and General ManagerOracle Health Sciences Global Business Unit

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Safe Harbor StatementThe following is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle’s products remains at the sole discretion of Oracle.

2

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Clinical R&D - What hasn’t Changed…

Improved Outcomes & Care Greater Safety

Reduced CostsStreamlined R&D

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Clinical R&D - What Continues to Change …

Science & Technology

Clinical R&D ProcessPatient Engagement

Clinical R&D Landscape

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 5

Oracle Health Sciences

Life Sciences

Healthcare

Continuum

Accelerate clinical developmentSupport entire drug safety lifecycleEnable clinical data aggregation

Power enterprise healthcare analytics Enable provider/payer integrationDrive personalized medicine

The movement from clinical research to clinical careDevelop collaboration networks for providers

and life sciences companies

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 6

Life Sciences

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Optimizing Clinical Research & Development

HEALTH SCIENCES CLOUD

Safety Lifecycle

Analytics and Insights

Signal Detection

Randomization & Trial Supply Management

Clinical Data Aggregation& Reporting

Comprehensive Electronic Data Capture

Trial Management& Monitoring

Planning & Budgeting

7

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Oracle Life Sciences

Broadest, best-of-breed applications

Focus on integration

The highest standards of scalability, security, and privacy

8

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Recent Oracle Life Sciences InnovationsMOBILITYINFORM, CRA & ANALYTICS

KEY PRODUCT & THIRD PARTY INTEGRATIONS

DATA MANAGEMENTWORKBENCH

INFORM ADVANCED MOLECULAR ANALYTICS

MEDICATION ADHERENCE (PROTEUS)

CLINICAL MONITORING CLOUD

REAL-WORLD SAFETY SURVEILLANCE & COMPARATIVE EFFECTIVENESS

RISK BASED MONITORING

9

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

• FDA-approved ingestible sensors

• Captures the body’s physiologic responses and behaviors

• Sends digital health information to a mobile app

• Oracle’s clinical trial applications customers have exclusive access to real-time data on therapeutic use

Medication Adherence

8

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Medication compliance insight

Better dose selection

Fewer Phase III failures

Improved drug safety

Medication Adherence

9

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

DEEP-ROOTED COMMITMENTTO DRIVING CLINICAL R&D PROCESS

OPTIMIZATIONAND ANALYTIC INSIGHTS

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 13

Healthcare

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Healthcare Providers are Facing:

Patient engagement and compliance

Care coordination Population health Precision medicine

Immediate Focus: Operational effectiveness Risk-based revenue

Evolves Over Time:

Changing business models and risk shifting

Margin pressure – cost, revenue, and volume

Consolidation pressure

Increased complexity in regulation

Aging population and management of chronic diseases

14

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Clinical Finance Human Resources Supply Chain Claims Genomics Research Clinical Trials 3rd Party Data

Client Developed Apps

Oracle Enterprise Healthcare

Analytics

Third Party Apps

Oracle Apps

Analyze NormalizeAggregate

Enabling Value ThroughMultiple & DisparateData Sources

Comprehensive Healthcare Data Model

Combines Clinical and OMICS Data

Data Governance

Productized Data Loaders Leverages Oracle Technology Application Choice

Powering Enterprise Healthcare Analytics

15

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 16

Continuum

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Delivers:

Biomarker discovery

Protocol validation and patient recruitment

Patient stratification

Safety and comparative effectiveness

Population health

Precision medicine

Harnessing Big Data for Life Sciences & Healthcare• Volume and availability of data continues to increase

• Data will have various strengths and significance

• Velocity of data is coming in faster than ever before

• Who better than Oracle to attack this?Sensors

Petabytes of information

Velocity of real-time data

Genomics

Variety of data sourcesReal-World Data

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Delivers:

Biomarker discovery

Protocol validation and patient recruitment

Patient stratification

Safety and comparative effectiveness

Population health

Precision medicineSensors

Petabytes of information

Velocity of real-time data

Genomics

Variety of data sourcesReal-World Data

Oracle Health

Sciences

Harnessing Big Data for Life Sciences & Healthcare

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 19

Effectiveness of Most Drugs

Major Drug Drug Effectiveness Cost of Ineffectivenessto Healthcare System

Source: The Personalized Medicine Coalition

Hypertension DrugsACE Inhibitors

10-30% $390 million – $1.2 billion

Anti Depressant DrugsSSRIs

20-50% $2.3 billion – $5.8 billion

Cholesterol Drugs Statins

30-70% $3.8 billion – $8.8 billion

Asthma Drugs Beta-2-agonists

40-70% $560 million – $1.0 billion

Heart Failure Drugs Beta Blockers

15-25% $345 million – $575 million

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Targeted treatments

More effective trials

Faster time to market

Improved safety

Dramatically lower costs

CURRENT TRANSFORMATION

Combining Clinical and OMICS data

Improving Population Health and Patient Outcomes

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

Healthcare Provider Participants

Life Sciences Participants While Ensuring:

Full control of de-identified data

Protection of Institutional IP

Respect for patient consent

Full HIPAA compliance

Oracle Health Sciences Network

Cloud-Based Collaborative R&D

Network Participants Include:

21

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | 22

Why Oracle Health Sciences?

COMMITTED INVESTMENT IN LIFE SCIENCES & HEALTHCARE

INDUSTRIAL STRENGTH CAPABILITY

DEEP & BROAD DATA MANAGEMENT

BEST-OF-BREED TECHNOLOGY

UNMATCHED DOMAIN EXPERTISE

INNOVATION & TRANSFORMATION

Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |

FROM PIPELINE TO PATIENTOPTIMIZING AND TRANSFORMING LIFE SCIENCES AND HEALTHCARE